Dômes Pharma the animal health company (previously TVM UK), has announced the launch of Fluoxevet, alongside Tessie, Bonqat and Sileo as part of its growing pet anxiety range. The range now offers vets different solutions when managing situational anxiety in cats and dogs.
Fluoxevet is the first re-engineered fluoxetine for dogs, offering accurate, flexible dosing in a double-divisible tablet, with a unique flavour profile to aid compliance.
Fluoxevet contains fluoxetine, a trusted molecule in a formulation made with vets and owners in mind. It is available as a single strength, double-divisible tablet making it a practical option for the long-term management of separation-related problems in dogs.
In the UK, separation-related problems in pets is an increasing concern, with 1.4 million dogs exhibiting signs of distress when left alone. Fluoxevet and Tessie offer vets both long-term and fast-acting treatment options, which can be used individually or in combination where appropriate and considered as part of a comprehensive approach to managing canine anxiety.
Jonathan Hill, UK country manager at Dômes Pharma says: "Dômes Pharma is really excited to be extending our pet anxiety range to help vets manage cases in this complex area. Fluoxevet expands our portfolio and provides essential options for owners and their pets struggling with situational related anxiety. We are committed to supporting veterinary practices and pet owners through our growing product range, technical support and pet owner information."
You can find more information here, contact Dômes Pharm here, or contact your local Territory Manager.